<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39364394</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2050-0068</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>10</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Clinical &amp; translational immunology</Title><ISOAbbreviation>Clin Transl Immunology</ISOAbbreviation></Journal><ArticleTitle>Humoral and cellular immune responses in vaccinated and unvaccinated children following SARS-CoV-2 Omicron infection.</ArticleTitle><Pagination><StartPage>e70008</StartPage><MedlinePgn>e70008</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70008</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/cti2.70008</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">The immune response in children elicited by SARS-CoV-2 Omicron infection alone or in combination with COVID-19 vaccination (hybrid immunity) is poorly understood. We examined the humoral and cellular immune response following SARS-CoV-2 Omicron infection in unvaccinated children and children who were previously vaccinated with COVID-19 mRNA vaccine.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Participants were recruited as part of a household cohort study conducted during the Omicron predominant wave (Jan to July 2022) in Victoria, Australia. Blood samples were collected at 1, 3, 6 and 12 months following COVID-19 diagnosis. Humoral immune responses to SARS-CoV-2 Spike proteins from Wuhan, Omicron BA.1, BA.4/5 and JN.1, as well as cellular immune responses to Wuhan and BA.1 were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 43 children and 113 samples were included in the analysis. Following Omicron infection, unvaccinated children generated low antibody responses but elicited Spike-specific CD4 and CD8 T-cell responses. In contrast, vaccinated children infected with the Omicron variant mounted robust humoral and cellular immune responses to both ancestral strain and Omicron subvariants. Hybrid immunity persisted for at least 6 months post infection, with cellular immune memory characterised by the generation of Spike-specific polyfunctional CD8 T-cell responses.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">SARS-CoV-2 hybrid immunity in children is characterised by persisting SARS-CoV-2 antibodies and robust CD4 and CD8 T-cell activation and polyfunctional responses. Our findings contribute to understanding hybrid immunity in children and may have implications regarding COVID-19 vaccination and SARS-CoV-2 re-infections.</AbstractText><CopyrightInformation>© 2024 The Author(s). Clinical &amp; Translational Immunology published by John Wiley &amp; Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Toh</LastName><ForeName>Zheng Quan</ForeName><Initials>ZQ</Initials><Identifier Source="ORCID">0000-0002-0282-5837</Identifier><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics The University of Melbourne Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics The University of Melbourne Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazarakis</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics The University of Melbourne Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quah</LastName><ForeName>Leanne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higgins</LastName><ForeName>Rachel A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Do</LastName><ForeName>Lien Anh Ha</ForeName><Initials>LAH</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics The University of Melbourne Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Yan Yung</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jalali</LastName><ForeName>Sedi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neeland</LastName><ForeName>Melanie R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics The University of Melbourne Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMinn</LastName><ForeName>Alissa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saffery</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McNab</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Medicine The Royal Children's Hospital Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McVernon</LastName><ForeName>Jodie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Peter Doherty Institute for Infection and Immunity The University of Melbourne Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcato</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Peter Doherty Institute for Infection and Immunity The University of Melbourne Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgner</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics The University of Melbourne Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Medicine The Royal Children's Hospital Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curtis</LastName><ForeName>Nigel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics The University of Melbourne Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Medicine The Royal Children's Hospital Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steer</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics The University of Melbourne Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Medicine The Royal Children's Hospital Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulholland</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics The University of Melbourne Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Epidemiology and Public Health London School of Hygiene and Tropical Medicine London UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pellicci</LastName><ForeName>Daniel G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics The University of Melbourne Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peter Doherty Institute for Infection and Immunity The University of Melbourne Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crawford</LastName><ForeName>Nigel W</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics The University of Melbourne Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Medicine The Royal Children's Hospital Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tosif</LastName><ForeName>Shidan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics The University of Melbourne Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Medicine The Royal Children's Hospital Parkville VIC Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Licciardi</LastName><ForeName>Paul V</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>Infection, Immunity and Global Health Murdoch Children's Research Institute Parkville VIC Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics The University of Melbourne Parkville VIC Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Clin Transl Immunology</MedlineTA><NlmUniqueID>101638268</NlmUniqueID><ISSNLinking>2050-0068</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS‐CoV‐2</Keyword><Keyword MajorTopicYN="N">cellular immune responses</Keyword><Keyword MajorTopicYN="N">children</Keyword><Keyword MajorTopicYN="N">hybrid immunity</Keyword></KeywordList><CoiStatement>NWC received funding from the National Institute of Health for influenza and COVID‐19 research. All other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>4</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39364394</ArticleId><ArticleId IdType="pmc">PMC11447454</ArticleId><ArticleId IdType="doi">10.1002/cti2.70008</ArticleId><ArticleId IdType="pii">CTI270008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alteri C, Scutari R, Costabile V et al. Epidemiological characterization of SARS‐CoV‐2 variants in children over the four COVID‐19 waves and correlation with clinical presentation. Sci Rep 2022; 12: 10194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9204374</ArticleId><ArticleId IdType="pubmed">35715488</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathanielsz J, Toh ZQ, Do LAH, Mulholland K, Licciardi PV. SARS‐CoV‐2 infection in children and implications for vaccination. Pediatr Res 2023; 93: 1177–1187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9376896</ArticleId><ArticleId IdType="pubmed">35970935</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P, Curtis N. Why does the severity of COVID‐19 differ with age?: Understanding the mechanisms underlying the age gradient in outcome following SARS‐CoV‐2 infection. Pediatr Infect Dis J 2022; 41: e36–e45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8740029</ArticleId><ArticleId IdType="pubmed">34966142</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed M, Advani S, Moreira A et al. Multisystem inflammatory syndrome in children: A systematic review. EClinicalMedicine 2020; 26: 100527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473262</ArticleId><ArticleId IdType="pubmed">32923992</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward JL, Harwood R, Kenny S et al. Pediatric hospitalizations and ICU admissions due to COVID‐19 and pediatric inflammatory multisystem syndrome temporally associated with SARS‐CoV‐2 in England. JAMA Pediatr 2023; 177: 947–955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10391354</ArticleId><ArticleId IdType="pubmed">37523172</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Almeida FJ, Baillie JK et al. International pediatric COVID‐19 severity over the course of the pandemic. JAMA Pediatr 2023; 177: 1073–1084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10442787</ArticleId><ArticleId IdType="pubmed">37603343</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez‐Leon S, Wegman‐Ostrosky T, Ayuzo Del Valle NC et al. Long‐COVID in children and adolescents: A systematic review and meta‐analyses. Sci Rep 2022; 12: 9950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9226045</ArticleId><ArticleId IdType="pubmed">35739136</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikkenborg Berg S, Palm P, Nygaard U et al. Long COVID symptoms in SARS‐CoV‐2‐positive children aged 0–14 years and matched controls in Denmark (LongCOVIDKidsDK): A national, cross‐sectional study. Lancet Child Adolesc Health 2022; 6: 614–623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9221683</ArticleId><ArticleId IdType="pubmed">35752194</ArticleId></ArticleIdList></Reference><Reference><Citation>Galmiche S, Charmet T, Rakover A et al. Risk of SARS‐CoV‐2 infection among households with children in France, 2020–2022. JAMA Netw Open 2023; 6: e2334084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10504612</ArticleId><ArticleId IdType="pubmed">37713194</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof SY, Slezak JM, Puzniak L et al. Effectiveness of a third dose of BNT162b2 mRNA COVID‐19 vaccine in a large US health system: A retrospective cohort study. Lancet Reg Health Am 2022; 9: 100198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8841530</ArticleId><ArticleId IdType="pubmed">35187521</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N, Stowe J, Kirsebom F et al. Effectiveness of COVID‐19 booster vaccines against COVID‐19‐related symptoms, hospitalization and death in England. Nat Med 2022; 28: 831–837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9018410</ArticleId><ArticleId IdType="pubmed">35045566</ArticleId></ArticleIdList></Reference><Reference><Citation>
(ATAGI) ATAGoI
. ATAGI update on the COVID‐19 vaccination program. https://www.health.gov.au/news/atagi‐update‐on‐the‐covid‐19‐vaccination‐program
</Citation></Reference><Reference><Citation>
Australia Department of Health
. COVID‐19 vaccine rollout update – 7 August 2022. https://www.health.gov.au/sites/default/files/documents/2022/08/covid‐19‐vaccine‐rollout‐update‐9‐august‐2022.pdf2022
</Citation></Reference><Reference><Citation>Piechotta V, Siemens W, Thielemann I et al. Safety and effectiveness of vaccines against COVID‐19 in children aged 5–11 years: A systematic review and meta‐analysis. Lancet Child Adolesc Health 2023; 7: 379–391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10112865</ArticleId><ArticleId IdType="pubmed">37084750</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A, Kani R, Iwagami M, Takagi H, Yasuhara J, Kuno T. Assessment of efficacy and safety of mRNA COVID‐19 vaccines in children aged 5 to 11 years: A systematic review and meta‐analysis. JAMA Pediatr 2023; 177: 384–394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9871947</ArticleId><ArticleId IdType="pubmed">36689319</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S. Hybrid immunity. Science 2021; 372: 1392–1393.</Citation></Reference><Reference><Citation>Reynolds CJ, Pade C, Gibbons JM et al. Prior SARS‐CoV‐2 infection rescues B and T cell responses to variants after first vaccine dose. Science 2021; 372: 1418–1423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8168614</ArticleId><ArticleId IdType="pubmed">33931567</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh HN, Chemaitelly H, Hasan MR et al. Protection against the omicron variant from previous SARS‐CoV‐2 infection. N Engl J Med 2022; 386: 1288–1290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8849180</ArticleId><ArticleId IdType="pubmed">35139269</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V, Foulkes S, Insalata F et al. Protection against SARS‐CoV‐2 after Covid‐19 vaccination and previous infection. N Engl J Med 2022; 386: 1207–1220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908850</ArticleId><ArticleId IdType="pubmed">35172051</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamatatos L, Czartoski J, Wan YH et al. mRNA vaccination boosts cross‐variant neutralizing antibodies elicited by SARS‐CoV‐2 infection. Science 2021; 372: 1413–1418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8139425</ArticleId><ArticleId IdType="pubmed">33766944</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrovitz N, Ware H, Ma X et al. Protective effectiveness of previous SARS‐CoV‐2 infection and hybrid immunity against the omicron variant and severe disease: A systematic review and meta‐regression. Lancet Infect Dis 2023; 23: 556–567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10014083</ArticleId><ArticleId IdType="pubmed">36681084</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazit S, Saciuk Y, Perez G et al. Hybrid immunity against reinfection with SARS‐CoV‐2 following a previous SARS‐CoV‐2 infection and single dose of the BNT162b2 vaccine in children and adolescents: A target trial emulation. Lancet Microbe 2023; 4: e495–e505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10101759</ArticleId><ArticleId IdType="pubmed">37062294</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh ZQ, Anderson J, Mazarakis N et al. Comparison of seroconversion in children and adults with mild COVID‐19. JAMA Netw Open 2022; 5: e221313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908077</ArticleId><ArticleId IdType="pubmed">35262717</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadfield J, Megill C, Bell SM et al. Nextstrain: Real‐time tracking of pathogen evolution. Bioinformatics 2018; 34: 4121–4123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6247931</ArticleId><ArticleId IdType="pubmed">29790939</ArticleId></ArticleIdList></Reference><Reference><Citation>Nantanee R, Jaru‐Ampornpan P, Chantasrisawad N et al. Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS‐CoV‐2 infection, in the era of omicron predominance. Vaccine X 2023; 15: 100367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10432840</ArticleId><ArticleId IdType="pubmed">37601322</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng W, Ma X, Tan K et al. Evaluation of cross‐neutralizing antibodies in children infected with omicron sub‐variants. Lancet Reg Health West Pac 2023; 40: 100939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10632766</ArticleId><ArticleId IdType="pubmed">37953966</ArticleId></ArticleIdList></Reference><Reference><Citation>Suntronwong N, Kanokudom S, Assawakosri S et al. Neutralizing antibodies against omicron BA.5 among children with infection alone, vaccination alone, and hybrid immunity. Int J Infect Dis 2023; 134: 18–22.</Citation><ArticleIdList><ArticleId IdType="pubmed">37207716</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, Pade C, Gibbons JM et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS‐CoV‐2 exposure. Science 2022; 377: eabq1841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9210451</ArticleId><ArticleId IdType="pubmed">35699621</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryawanshi RK, Chen IP, Ma T et al. Limited cross‐variant immunity from SARS‐CoV‐2 omicron without vaccination. Nature 2022; 607: 351–355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9279157</ArticleId><ArticleId IdType="pubmed">35584773</ArticleId></ArticleIdList></Reference><Reference><Citation>Qui M, Hariharaputran S, Hang SK et al. T cell hybrid immunity against SARS‐CoV‐2 in children: A longitudinal study. EBioMedicine 2024; 105: 105203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11237860</ArticleId><ArticleId IdType="pubmed">38896919</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury DS, Schlub TE, Cromer D et al. Correlates of protection, thresholds of protection, and immunobridging among persons with SARS‐CoV‐2 infection. Emerg Infect Dis 2023; 29: 381–388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9881762</ArticleId><ArticleId IdType="pubmed">36692375</ArticleId></ArticleIdList></Reference><Reference><Citation>Cromer D, Steain M, Reynaldi A et al. Neutralising antibody titres as predictors of protection against SARS‐CoV‐2 variants and the impact of boosting: A meta‐analysis. Lancet Microbe 2022; 3: e52–e61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8592563</ArticleId><ArticleId IdType="pubmed">34806056</ArticleId></ArticleIdList></Reference><Reference><Citation>Regev‐Yochay G, Lustig Y, Joseph G et al. Correlates of protection against COVID‐19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS‐CoV‐2 in households in Israel (ICoFS): A prospective cohort study. Lancet Microbe 2023; 4: e309–e318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10030121</ArticleId><ArticleId IdType="pubmed">36963419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DY, Gu Y, Xu Y et al. Effects of vaccination and previous infection on omicron infections in children. N Engl J Med 2022; 387: 1141–1143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9511630</ArticleId><ArticleId IdType="pubmed">36069811</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowell AC, Lancaster T, Bruton R et al. Immunological imprinting of humoral immunity to SARS‐CoV‐2 in children. Nat Commun 2023; 14: 3845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10310754</ArticleId><ArticleId IdType="pubmed">37386081</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent SJ, Khoury DS, Reynaldi A et al. Disentangling the relative importance of T cell responses in COVID‐19: Leading actors or supporting cast? Nat Rev Immunol 2022; 22: 387–397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047577</ArticleId><ArticleId IdType="pubmed">35484322</ArticleId></ArticleIdList></Reference><Reference><Citation>Phan JM, Layton ED, Yu KKQ et al. Cytotoxic T cells targeting spike glycoprotein are associated with hybrid immunity to SARS‐CoV‐2. J Immunol 2023; 210: 1236–1246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10121904</ArticleId><ArticleId IdType="pubmed">36961450</ArticleId></ArticleIdList></Reference><Reference><Citation>Brasu N, Elia I, Russo V et al. Memory CD8+ T cell diversity and B cell responses correlate with protection against SARS‐CoV‐2 following mRNA vaccination. Nat Immunol 2022; 23: 1445–1456.</Citation><ArticleIdList><ArticleId IdType="pubmed">36138186</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV et al. Impact of COVID‐19 vaccination on the risk of developing long‐COVID and on existing long‐COVID symptoms: A systematic review. EClinicalMedicine 2022; 53: 101624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuodi P, Gorelik Y, Zayyad H et al. Association between BNT162b2 vaccination and reported incidence of post‐COVID‐19 symptoms: Cross‐sectional study 2020–21, Israel. NPJ Vaccines 2022; 7: 101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9411827</ArticleId><ArticleId IdType="pubmed">36028498</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of first dose of covid‐19 vaccine versus no vaccination on symptoms of patients with long covid: Target trial emulation based on ComPaRe e‐cohort. BMJ Med 2023; 2: e000229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9978748</ArticleId><ArticleId IdType="pubmed">36910458</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello R, Mariani F, Mastrantoni L et al. Risk factors for post‐COVID‐19 condition (Long Covid) in children: A prospective cohort study. EClinicalMedicine 2023; 59: 101961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10101848</ArticleId><ArticleId IdType="pubmed">37073325</ArticleId></ArticleIdList></Reference><Reference><Citation>Kissler SM, Fauver JR, Mack C et al. Viral dynamics of SARS‐CoV‐2 variants in vaccinated and unvaccinated persons. N Engl J Med 2021; 385: 2489–2491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8693673</ArticleId><ArticleId IdType="pubmed">34941024</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan AT, Linster M, Tan CW et al. Early induction of functional SARS‐CoV‐2‐specific T cells associates with rapid viral clearance and mild disease in COVID‐19 patients. Cell Rep 2021; 34: 108728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7826084</ArticleId><ArticleId IdType="pubmed">33516277</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan JM, Mateus J, Kato Y et al. Immunological memory to SARS‐CoV‐2 assessed for up to 8 months after infection. Science 2021; 371: eabf4063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg Y, Mandel M, Bar‐On YM et al. Protection and waning of natural and hybrid immunity to SARS‐CoV‐2. N Engl J Med 2022; 386: 2201–2212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9165562</ArticleId><ArticleId IdType="pubmed">35613036</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacco C, Del Manso M, Mateo‐Urdiales A et al. Effectiveness of BNT162b2 vaccine against SARS‐CoV‐2 infection and severe COVID‐19 in children aged 5–11 years in Italy: A retrospective analysis of January–April, 2022. Lancet 2022; 400: 97–103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9246475</ArticleId><ArticleId IdType="pubmed">35780801</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh ZQ, Mazarakis N, Nguyen J et al. Comparison of antibody responses to SARS‐CoV‐2 variants in Australian children. Nat Commun 2022; 13: 7185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9700848</ArticleId><ArticleId IdType="pubmed">36434068</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J, Novak T, Hecker J et al. Cross‐reactive immunity against the SARS‐CoV‐2 omicron variant is low in pediatric patients with prior COVID‐19 or MIS‐C. Nat Commun 2022; 13: 2979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9142524</ArticleId><ArticleId IdType="pubmed">35624101</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh ZQ, Higgins RA, Do LAH et al. Persistence of SARS‐CoV‐2‐specific IgG in children 6 months after infection, Australia. Emerg Infect Dis 2021; 27: 2233–2235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314814</ArticleId><ArticleId IdType="pubmed">34016252</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>